Stilla Technologies, a Paris, France-based provider of digital PCR (dPCR) solutions for high-precision genetic analysis, raised €20m ($22m) in Series B funding.
The round was led by TUS-Holdings, with participation from existing investors Illumina Ventures, Kurma Partners, LBO France, Paris Saclay Seed Funds, BNP Paribas Développement and Idinvest Partners. In conjunction with the funding, Daniel Wang, Head of TUS’ European subsidiary, joined Stilla as a new member of the board.
The company will use the funds to boost the development of its solution, which will feature high analytical performance including 6-color detection capabilities.
Founded in 2013 at Ecole Polytechnique by Rémi Dangla, CEO, Stilla Technologies provides research organizations specialized in molecular biology and genetic analysis with its Naica System, a digital PCR (polymerase chain reaction) solution that enables scientists to detect and quantify DNA mutations with unrivalled precision.
The company launched the first generation of the Naica™ System in 2016 and generated first revenues in 2017.